Skip to Content

Davabazaar in India Vision and Objective

Sun, 10/11/2009 - 14:34 — Bhekare

Davabazaar in India website is a Pharma Trade Portal which caters to end patients and their relatives, chemist and medical stores, pharmacist and other pharma workers, doctors and nursing homes, hospitals and medical institutions, pharmaceutical manufactures and allied service providers, trade and manufactures associations.

For patients and relatives we have Ask-the-Doctor medical forums, health blogs, chats and patient health communities.

Drug Index Software

Mon, 10/05/2009 - 15:58 — Correspondent

Very soon the drug index software will be available for download. This software and all further upgrades are available free of cost to chemist and medical doctors. Please register and get yourself verified. Pharmaceutical companies who wish to add their information should also register and get verified.

Correspondent's picture

Pharma Overview

Wed, 08/12/2009 - 00:24 — Correspondent

Pharmaceutical OverviewLast Updated: April 2009

Sector structure/Market size


The Indian pharmaceutical industry is driving product development and breaking new grounds in medicine research worldwide.


The Indian domestic pharmaceutical market is estimated to be US$ 10.76 billion in 2008 and is expected to grow at a high compound annual growth rate (CAGR) of 9.9 per cent till 2010 and thereafter at a CAGR of 9.5 per cent till 2015.

Correspondent's picture

Encap Drug Delivery Receives Patent Approval For DuoCapTM Capsule System

Thu, 07/29/2010 - 13:30 — Correspondent

Encap Drug Delivery, a leading provider of development and manufacturing services to the pharmaceutical industry, has received confirmation that their DuoCapTM, capsule delivery system has been granted patents for US and Europe. DuoCapTM, is a single oral dosage unit that comprises a capsule-in-a-capsule and offers broad therapeutic applications...

Correspondent's picture

FDA Grants Priority Review to Cladribine Tablets

Thu, 07/29/2010 - 04:30 — Correspondent

Merck KGaA announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS).

Correspondent's picture

Allos’ NSCLC Drug Folotyn Extends Overall Survival

Thu, 07/29/2010 - 01:30 — Correspondent

Allos Therapeutics’ Folotyn demonstrated clinical activity compared with Genentech/OSI Pharmaceuticals’ Tarceva in a second-line treatment study of advanced non-small cell lung cancer (NSCLC) patients, top-line results show.

Correspondent's picture

FDA Advisory Panel Votes to Approve AstraZeneca’s Brilinta

Thu, 07/29/2010 - 01:30 — Correspondent

An FDA advisory committee has recommended approval of AstraZeneca’s blood thinner Brilinta.

Correspondent's picture

Full Issue

Thu, 07/29/2010 - 01:30 — Correspondent

View the entire issue.

Correspondent's picture

FDA Advisory Committees’ Waivers Would Become Public Under House Bill

Thu, 07/29/2010 - 01:30 — Correspondent

Advisory committee member waivers, including those granted by the FDA, would have to be publicly disclosed 15 days before each meeting, under a bill passed Monday by the House.

Correspondent's picture

FTC Sees Rise in Pay-For-Delay Settlements

Thu, 07/29/2010 - 01:30 — Correspondent

With three months left in fiscal 2010, the FTC has seen a rise in the number of “pay-for-delay” settlements between brand- and generic-drug makers, with 21 recorded between October 2009 and June 2010.

Correspondent's picture

FDA Advisory Panel to Consider Surrogate Endpoints for Pediatric PAH Drugs

Thu, 07/29/2010 - 01:30 — Correspondent

An FDA advisory committee will debate whether using pulmonary vascular resistance index (PVRI) changes rather than changes in exercise capacity is an effective endpoint to use in clinical trials evaluating pulmonary arterial hypertension (PAH) drugs in children.

Correspondent's picture

Advanced Biofuel Trade Associations Express Support For Tax Policy On Second-Generation Biofuels

Wed, 07/28/2010 - 20:30 — Correspondent

As Congress takes action on critical tax incentive packages, the leading advanced biofuel trade associations reemphasized the importance of advanced biofuels as promising opportunities for the United States to reduce its reliance on oil and create green jobs. Sustained and diverse federal programs, including tax incentives, can help producers secure financing for construction of projects...

Correspondent's picture

Report: Generic Drugs Offer Savings For Medicaid

Wed, 07/28/2010 - 16:30 — Correspondent

A new report suggests that expanding use of generic drugs could offer significant savings for Medicaid. "Every 2% uptick in the substitution of generic drugs for brand-name products saves Medicaid $1 billion a year, according to a report released by the Generic Pharmaceutical Association (GPhA)," The Wall Street Journal's Health Blog reports...

Correspondent's picture

PhRMA Asks FDA To Be More Straightforward On Safeguards It Wants To Fight Drug Risks

Wed, 07/28/2010 - 16:30 — Correspondent

The pharmaceutical industry trade group PhRMA said Monday that the Food and Drug Administration should do a better job of explaining additional safeguards it mandates against certain drugs when it issues warnings, Reuters reports...

Correspondent's picture

New Study Reveals UK Patients Are Less Likely To Receive Innovative Medicines

Wed, 07/28/2010 - 16:30 — Correspondent

One of the most comprehensive reports comparing the use of medicines in the UK with that in other countries has been published by the Department of Health. The report shows that the UK still lags behind comparable countries in Europe and elsewhere on its use of newer cancer treatments and medicines for chronic diseases such as rheumatoid arthritis, multiple sclerosis and dementia...

Correspondent's picture

MabCure, Inc. Announces Positive Results For New Ovarian Cancer Diagnostic Blood Test

Wed, 07/28/2010 - 14:30 — Correspondent

Biotechnology company MabCure, Inc. (OTC Bulletin Board: MBCI) announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood...

Correspondent's picture

Omeros Enrolls First Patient In Phase 2b Clinical Trial Evaluating OMS302 In Patients Undergoing Cataract Surgery

Wed, 07/28/2010 - 14:30 — Correspondent

Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it has enrolled the first patient in its Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery...

Correspondent's picture

DIATHERIX Laboratories Launches STD And HSV Test Panel

Wed, 07/28/2010 - 14:30 — Correspondent

DIATHERIX Laboratories, adds a Sexually Transmitted Disease (STD) panel and Herpes Simplex Virus (HSV) panel to its line up of highly sensitive, rapid response diagnostic panels. The HSV panel identifies herpes simplex viruses 1 and 2 and the STD panel identifies 10 sexually transmitted diseases simultaneously, many of which cannot be accurately identified by current testing methods...

Correspondent's picture

FDA Approves Orthovita's New Collagen Facility

Wed, 07/28/2010 - 13:30 — Correspondent

Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, reported that the U.S. Food and Drug Administration (FDA) approved Orthovita's PMA supplement for a new collagen processing facility in Malvern, Pennsylvania. Orthovita will use the new facility to process the highly purified form of collagen used in its VITAGEL™ Surgical Hemostat product...

Correspondent's picture

Boston University Wins $1.6M NIH Grant To Target Protein-Protein Interactions

Wed, 07/28/2010 - 12:30 — Correspondent

An interdisciplinary team of Boston University professors is launching a project to develop new ways to target protein-protein interactions with synthetic organic drugs. Financed by a four-year $1...

Correspondent's picture

Lilly Reports Strong Second-Quarter 2010 Results

Wed, 07/28/2010 - 04:30 — Correspondent

Eli Lilly and Company (NYSE: LLY) announced financial results for the second quarter of 2010. In the second quarter of 2010, worldwide total revenue was $5.749 billion, an increase of 9 percent compared with the second quarter of 2009.

Correspondent's picture

FDA Reviewers Question Efficacy Differences in Brilinta Trials

Wed, 07/28/2010 - 01:30 — Correspondent

Although AstraZeneca’s blood thinner Brilinta has demonstrated strong efficacy, FDA drug reviewers are raising questions about differences in the drug’s effectiveness between U.S. and ex-U.S. clinical trials.

Correspondent's picture

Antares’ Anturol Succeeds in Phase III for Overactive Bladder

Wed, 07/28/2010 - 01:30 — Correspondent

Antares’ overactive bladder (OAB) gel Anturol demonstrated positive Phase III results, positioning it as a potential competitor to other treatments, such as Watson’s Gelnique.

Correspondent's picture

Full Issue

Wed, 07/28/2010 - 01:30 — Correspondent

View the entire issue.

Correspondent's picture

NICE to Reconsider Celgene’s Vidaza for Severe Blood Disorder

Wed, 07/28/2010 - 01:30 — Correspondent

The UK’s National Institute for Health and Clinical Excellence will reappraise Celgene’s Vidaza (azacitidine) in patients with higher-risk myelodysplastic syndrome (MDS), following separate appeals by Celgene and a coalition of patient and professional groups.

Correspondent's picture

Teva Says Clinical Trials Necessary for a Copaxone Generic

Wed, 07/28/2010 - 01:30 — Correspondent

Any generic version of Teva’s blockbuster multiple sclerosis treatment Copaxone would need clinical trials to gain approval, the company says in response to speculation that the FDA might approve a generic Copaxone using the same criteria as applied to generic Lovenox.

Correspondent's picture

** DID 3

Wed, 07/28/2010 - 01:30 — Correspondent
Correspondent's picture

Sanofi Seeks Injunction to Block Generic Lovenox Sales

Wed, 07/28/2010 - 01:30 — Correspondent

Sanofi-Aventis is asking a federal judge to issue an injunction blocking the sale of a generic version of Lovenox on the grounds that the FDA improperly approved the ANDA.

Correspondent's picture

Wellcome Trust Grant To King's College London To Combat Counterfeit Drugs, UK

Tue, 07/27/2010 - 20:30 — Correspondent

The Wellcome Trust has awarded £473,000 to a team of King's researchers, to be led by Dr Kaspar Althoefer, Reader in Sensing and Embedded Systems, for the creation of a system that can identify counterfeit and substandard drugs...

Correspondent's picture

Also In Global Health News: NIH And Rare Diseases; Cold Emergency In Peru; U.S.-Russia Emergency Cooperation Pact

Tue, 07/27/2010 - 15:30 — Correspondent

NIH Program Pilots Drug Development For Schistosomiasis, Other Rare Diseases The NIH Therapeutics for Rare and Neglected Diseases (TRND) program has "launched five pilot projects that are taking the [NIH] in a new direction: developing drugs," writes the Wall Street Journal. Among the projects is one that targets "drug development ...

Syndicate content


Theme by Dr. Radut.